Humacyte Q1 net loss $37M; secures second RMAT for HAV in vascular trauma, plans BLA filing in 2023

Humacyte, Inc.

2023-Q1 EPS reported -$0.36

Net loss of $37.0M in Q1 2023 vs $19.8M in Q1 2022; cash & investments $131.7M at March 31, 2023.
Received second FDA RMAT designation for HAV in urgent arterial repair after extremity vascular trauma.
Completed enrollment in Phase 3 hemodialysis access trial (240 patients); top-line results expected in 2024.
Plans to file BLA with FDA later in 2023 for HAV in vascular trauma; V005 trial enrolled 66 patients.
Subsequent to Q1, secured up to $160M funding arrangement with Oberland Capital to fund operations past potential approval.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Humacyte, Inc. reported the first quarter of 2023 results: net income $37.0 million.

Period: the first quarter of 2023
Net income: $37.0 million
Result: reported results

Exact text from the filing

Net loss was $37.0 million for the first quarter of 2023, compared to $19.8 million for the first quarter of 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-23-000028

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.